High Yield Markets
  • World News
  • Politics
  • Investing
  • Stock
  • Editor’s Pick
Politics

Dr. McCullough Weighs In: The History & Future of GLP-1s

by March 29, 2025
March 29, 2025

(Note: Thank you for supporting businesses like the one presenting a sponsored message below and working with them through the links below which benefits Gateway Pundit. We appreciate your support!)

In a recent article by Dr. Peter McCullough, he explores the evolution of GLP-1 receptor agonists and their expanding role beyond diabetes treatment.

The journey began in 2005 with the FDA approval of exenatide (Byetta), setting the stage for a new class of medications that regulate blood sugar and appetite.

A Timeline of GLP-1 Advancements:

2005 – Exenatide (Byetta) approved for type 2 diabetes
2010 – Liraglutide (Victoza) enters the market
2017 – Semaglutide (Ozempic & oral Rybelsus) gains approval
2022 – Tirzepatide (Mounjaro) emerges as a dual-receptor agonist

These drugs influence key metabolic pathways, offering benefits for both diabetes and weight loss. However, they come with limitations—most require injections, clinical oversight, and ongoing prescriptions.

The Next Step: Retatrutide & The Power of Triple-Receptor Agonism

As Dr. McCullough discusses, retatrutide (LY3437943) represents the next evolution in GLP-1 therapies, targeting three key receptors:

– GLP-1 for appetite control & glucose regulation
– GIP to enhance insulin sensitivity
– Glucagon to promote fat metabolism

While injectable retatrutide is still under clinical investigation, early data suggests it is more effective than its predecessors. However, many individuals want a more flexible, private, and patient-controlled solution for weight loss.

Introducing DROP: A Revolutionary Approach to Weight Management

The Wellness Company developed DROP — an oral retatrutide formula — designed to support metabolic health without the barriers of traditional GLP-1 therapies.

Encapsulated in liposomes for enhanced absorption, DROP provides an alternative solution for those seeking appetite control and weight management in a non-injectable form.

If you’ve considered GLP-1 treatments but want a more discreet, adaptable option, click here to see if DROP may be the solution you’ve been looking for.

Your healthier alternative is here.

No needles. No restrictive diets. Just a smarter approach to weight management.

Click here to see if DROP is right for you.

Note: The information provided on this website is intended for informational purposes only and should not be considered medical advice or used as a substitute for professional healthcare guidance. It is your responsibility to comply with all applicable laws, regulations, and guidelines regarding the purchase, possession, and use of prescription medications.

The post Dr. McCullough Weighs In: The History & Future of GLP-1s appeared first on The Gateway Pundit.

previous post
WATCH: Arizona Secretary of State Adrian Fontes Says he Plans to Violate Federal Election Law – “Tell Them to Go to Hell”
next post
The Signal Chat Scandal—A Tempest in a Teacup, Not an Actionable Offense

You may also like

Iran’s Chilling THREAT to Trump: Sleeper Cells Ready...

June 24, 2025

Sean ‘Diddy’ Combs Trial: Defense Will Reportedly Present...

June 24, 2025

OMG: NY State Senior Health Department Lawyer Claims...

June 24, 2025

WATCH: “So Discourteous!” – Unhinged Democrat Rep. Triggered...

June 24, 2025

RFK Jr. Announces “Health Insurance Breakthrough” That Affects...

June 24, 2025

Trump DHS Responds After Judge Rules MS-13 Gang...

June 24, 2025

Leftists Lose It After President Trump Gives CNN’s...

June 23, 2025

NEW: Iran’s Supreme Leader Ayatollah Ali Khamanei Posts...

June 23, 2025

BREAKING: Trump Announces Israel and Iran Have Agreed...

June 23, 2025

Wayne Root Reports on Proof of the Stolen...

June 23, 2025
Join The Exclusive Subscription Today And Get Premium Articles For Free


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Recent Posts

  • The FDA’s Biosimilar Burden—and How Congress Can Lift It

    June 23, 2025
  • Election Policy Roundup

    June 23, 2025
  • Congress Should Let the New Markets Tax Credit Expire

    June 23, 2025
  • A Common Thread: Price Controls, Japanese Internment, and the Little Rock Nine

    June 23, 2025
  • Can Mail Ballots Be Lawfully Counted If Received After Election Day? Where the Law Stands

    June 23, 2025
  • About Us
  • Contacts
  • Privacy Policy
  • Terms and Conditions
  • Email Whitelisting

Copyright © 2025 highyieldmarkets.com | All Rights Reserved

High Yield Markets
  • World News
  • Politics
  • Investing
  • Stock
  • Editor’s Pick